Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 19

1.

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakova D, Annovazzi P, Novelli F, Durelli L, Clerico M.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194. doi: 10.1212/NXI.0000000000000194. eCollection 2016 Feb.

2.

Progression of multiple sclerosis is associated with gender differences in glutathione S-transferase P1 detoxification pathway.

Bačić Baronica K, Mlinac K, Petlevski R, Ozretić D, Vladić A, Kalanj-Bognar S, Zuntar I.

Acta Neurobiol Exp (Wars). 2014;74(3):257-65.

3.

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators.

Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.

PMID:
24794721
4.

Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.

Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J.

J Clin Endocrinol Metab. 2014 Jan;99(1):80-9. doi: 10.1210/jc.2013-2201. Epub 2013 Dec 20.

PMID:
24170099
5.

"Compensated hyperosmolarity" of cerebrospinal fluid and the development of hydrocephalus.

Klarica M, Miše B, Vladić A, Radoš M, Orešković D.

Neuroscience. 2013 Sep 17;248:278-89. doi: 10.1016/j.neuroscience.2013.06.022. Epub 2013 Jun 24.

PMID:
23806710
6.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators.

Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.

PMID:
23122652
7.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
8.

Recommendations for diagnosis and management of multiple sclerosis.

Kes VB, Zavoreo I, Serić V, Solter VV, Cesarik M, Hajnsek S, Pasić MB, Gabelić T, Silvio B, Butković SS, Lusić I, Grbelja LD, Vladić A, Bielen I, Antoncić I, Demarin V; Croatian Society for Neurovascular Disorders of Croatian Medical Association; Croatian Society of Neurology of Croatian Medical Association; Referral Center for Demyelinating Diseases of the CNS.

Acta Clin Croat. 2012 Mar;51(1):117-35.

PMID:
22920014
9.

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.

PMID:
22442431
10.

Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.

Baronica KB, Mlinac K, Ozretić D, Vladić A, Bognar SK.

Coll Antropol. 2011 Jan;35 Suppl 1:11-6.

PMID:
21648305
11.

Prevalence and socioeconomic aspects of epilepsy in the Croatian county of Sibenik-Knin: community-based survey.

Josipovic-Jelic Z, Sonicki Z, Soljan I, Demarin V; Collaborative Group for Study of Epilepsy Epidemiology in Sibenik-Knin County, Croatia.

Epilepsy Behav. 2011 Apr;20(4):686-90. doi: 10.1016/j.yebeh.2011.02.008. Epub 2011 Mar 13.

PMID:
21402499
12.

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5.

PMID:
21397567
13.

Dynamics of distribution of 3H-inulin between the cerebrospinal fluid compartments.

Vladić A, Klarica M, Bulat M.

Brain Res. 2009 Jan 12;1248:127-35. doi: 10.1016/j.brainres.2008.10.044. Epub 2008 Oct 31.

PMID:
19007752
14.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK.

N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.

15.

Monoamine oxidases A and B gene polymorphisms in migraine patients.

Filic V, Vladic A, Stefulj J, Cicin-Sain L, Balija M, Sucic Z, Jernej B.

J Neurol Sci. 2005 Feb 15;228(2):149-53. Epub 2004 Dec 24.

PMID:
15694196
16.

Platelet serotonin measures in migraine.

Jernej B, Vladić A, Cicin-Sain L, Hranilović D, Banović M, Balija M, Bilić E, Sucić Z, Vukadin S, Grgicević D.

Headache. 2002 Jul-Aug;42(7):588-95.

PMID:
12482210
18.

Homeostatic role of the active transport in elimination of [3H]benzylpenicillin out of the cerebrospinal fluid system.

Vladić A, Strikić N, Jurcić D, Zmajević M, Klarica M, Bulat M.

Life Sci. 2000 Sep 29;67(19):2375-85.

PMID:
11065184
19.

Effect of active transport on distribution and concentration gradients of [3H]benzylpenicillin in the cerebrospinal fluid.

Strikić N, Klarica M, Vladić A, Bulat M.

Neurosci Lett. 1994 Mar 14;169(1-2):159-62.

PMID:
8047274
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk